1st independent French pharmaceutical company

Over 21 000 employees, including nearly 3000 researchers preparing the drugs of the future

27% of turnover invested in Research and Development

44 new chemical entities currently under development in the following therapeutic fields: cardiovascular diseases, central nervous system and psychiatry, cancer research, diabetes and metabolism, and rheumatology

Present in 140 countries over 5 continents

91% of Servier's medicines are prescribed internationally

A turnover of 4.2 billion euros for 2013